JAK ACADEMY in Rheumatoid Arthritis (RA)

JAK ACADEMY in Rheumatoid Arthritis (RA)

Authors

  • Roberto Caporali Associate Professor of Rheumatology, Pavia University, Director of the Early Arthritis Clinic of the IRCCS Foundation Policlinico San Matteo di Pavia, Pavia (Italy)
  • Marcello Govoni Associate Professor of Rheumatology, University of Ferrara. Head UOC Reumatologia - Azienda Ospedaliero Universitaria S. Anna - Ferrara (Italy)
  • Giovanni Lapadula Full Professor, Department of Emergency and Organ Transplants, Bari (Italy)
  • Luigi Sinigaglia Director of the Department of Rheumatology and Medical Sciences Centro Ortopedico Traumatologico Gaetano Pini-CTO, Milano (Italy)
  • Guido Valesini Full Professor of Rheumatology, Director of the Rheumatology Specialisation School, Sapienza Università di Roma. Coordinator of the Research Doctorate in Clinical and Experimental Rheumatology, Rome (Italy)

DOI:

https://doi.org/10.19156/abtpn.2018.0033

Keywords:

Rheumatoid arthritis, JAK

Abstract

The latest update of the EULAR recommendations for the treatment of RA maintain csDMARD (conventional systemic DMARDs) as the first line treatment, with methotrexate (MTX) still identified as the anchor drug, to which it is possible to add, in failure patients with negative prognostic factors, a biological drug or a tsDMARD (target synthetic DMARD), i.e JAK inhibitors.

Downloads

Download data is not yet available.

Downloads

Published

2018-09-10

How to Cite

Caporali, R., Govoni, M., Lapadula, G., Sinigaglia, L., & Valesini, G. (2018). JAK ACADEMY in Rheumatoid Arthritis (RA): JAK ACADEMY in Rheumatoid Arthritis (RA). AboutOpen, 4(1), 11–12. https://doi.org/10.19156/abtpn.2018.0033

Issue

Vol. 4 No. 1 (2018): January - December 2018

Section

Brief report

License

Copyright (c) 2018 The authors

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Metrics

Crossref
Scopus
Google Scholar
Europe PMC